# Taste changes (dysgeusia) during cancer treatment

Source: https://onco.cc/protocols/taste-changes-during-cancer-treatment/  
OnCo record `taste-changes-during-cancer-treatment` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Many cancer treatments change how food tastes: bland, metallic, bitter or too sweet. It often improves after treatment ends, but not always, and no medicine reliably prevents or reverses it. What helps is practical: trying different foods, mouth care, and a dietitian if you eat less or lose weight. On talquetamab or tarlatamab, tell your team promptly. Your own team's advice comes first.

## Summary

No source read gives a graded recommendation for taste change. The MASCC/ISOO systematic review (Hovan 2010, read as an abstract) found a weighted prevalence of 56 to 76% depending on the type of cancer treatment and concluded that there does not appear to be a predictable way of preventing or treating dysgeusia. The NCI PDQ summary says that taste change with chemotherapy is generally reversible, with taste returning to normal in the ensuing months.

The MASCC/ISOO clinical practice statement on immunotherapy (2025, expert opinion, ungraded) asks clinicians to exclude a concurrent drug or oral hygiene product, to rule out a nutritional deficit with a blood count, iron panel, folic acid, zinc and vitamin B tests, and to check thyroid function. It says a short empirical course of a topical antifungal or antimicrobial may be a strategy to exclude oral infection, that zinc may be a treatment option (on the basis of studies in the general population), and that the response to any treatment may be slow and unpredictable. On zinc the evidence disagrees: two placebo-controlled trials found no benefit (Halyard 2007, 169 patients having head and neck radiotherapy; Lyckholm 2012, 58 patients on chemotherapy), a 2020 meta-analysis of three radiotherapy studies found a lower incidence of dysgeusia with zinc (risk ratio 0.72, 95% CI 0.67 to 0.92) and no faster recovery, and a 2024 systematic review of 12 articles called zinc promising. The rest is practical advice from NCI, Cancer Research UK and Macmillan, with referral to a dietitian.

Talquetamab is the one product with a label rule. US label (revised 10/2025): oral toxicity in 80% of patients, not resolved to baseline in 65%; dysgeusia cannot be graded above 2 under CTCAE v4.03; Grade 1 to 2 oral toxicity or weight loss, provide supportive care and consider withholding if not responsive; Grade 3, withhold until Grade 1 or better; Grade 4, permanently discontinue. EU SmPC: for toxicity not responding to supportive care, interrupt until stabilisation or improvement and consider restarting less often (0.4 mg/kg weekly to every two weeks; 0.8 mg/kg every two weeks to every four weeks); its oral toxicity row has no grades. Both ask for weight to be monitored regularly. The US tarlatamab label counts dysgeusia (34%) among neurologic toxicities and its Medication Guide asks patients to report changes in taste right away. Its general instruction is to withhold at the first sign of neurologic toxicity, including ICANS, and consider neurology evaluation; its dose table is graded for ICANS only, and it does not say how the instruction applies to taste change alone. The EU product information lists it as a very common side effect only.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: dysgeusia; ageusia; loss of taste; metallic taste; taste alteration; food tastes different on chemotherapy; talquetamab taste changes; GPRC5D oral toxicity

## Connected records

- protocols: [Dry mouth from radioactive iodine, PSMA radioligand therapy and cancer drugs](https://onco.cc/protocols/dry-mouth-from-cancer-drugs-and-radionuclide-therapy/), [Nutrition screening and support during cancer treatment](https://onco.cc/protocols/nutrition-screening-and-support-during-cancer-treatment/), [Oral care and oral mucositis prevention during cancer treatment](https://onco.cc/protocols/oral-mucositis-prevention-and-oral-care/), [T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery](https://onco.cc/protocols/bispecific-step-up-dosing/)
- technologies: [Dry mouth, teeth and taste after head and neck radiotherapy](https://onco.cc/technologies/dry-mouth-teeth-after-head-neck-radiotherapy/)
- targets: [GPRC5D](https://onco.cc/targets/gprc5d/)
- drugs: [Talquetamab](https://onco.cc/drugs/talquetamab/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/)

---
JSON: https://onco.cc/api/v1/entities/taste-changes-during-cancer-treatment.json